Vertex presents positive long-term data on casgevy™ (exagamglogene autotemcel) at the 2024 annual european hematology association (eha) congress

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced longer-term data for casgevy™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (scd) or transfusion-dependent beta thalassemia (tdt). the results, presented at the annual european hematology association (eha) congress, confirm the transformative, consistent and durable clinical benefits of casgevy over time. casgevy is the first and only approved.
VRTX Ratings Summary
VRTX Quant Ranking